Meeting
2018 ASCO Annual Meeting
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
Authors
Eytan Stein
Memorial Sloan Kettering Cancer Center, New York, NY
Eytan Stein , Courtney Denton Dinardo , Jun Ho Jang , Yasushi Miyazaki , Roberto Ovilla Martinez , Julia Auer , Vickie Zhang , Daniel O. Koralek , Bin Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03173248
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7074)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7074
Abstract #
TPS7074
Poster Bd #
133b
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
First Author: Ghassan K. Abou-Alfa
Poster
2017 ASCO Annual Meeting
ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.
First Author: Maeve Aine Lowery
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world testing, treatment patterns, and outcomes following liquid biopsy in advanced cholangiocarcinoma.
First Author: Amit Mahipal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer